Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Today’s rally breaks the stock into new-high territory in a clear move by investors to start buying HIM stock ahead of its next quarterly report on March 3. The move is also being fueled by a positive ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Hims & Hers Health (NYSE: HIMS) is a relatively young company addressing age-old healthcare challenges by offering ...

Telehealth company's spot decries medications from others as "priced for profits, not patients," while its own weight-loss ...

The millennial-targeted telehealth company Hims & Hers (HIMS) is spending big bucks on its first ever Super Bowl commercial ...

Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

The Super Bowl spot is part of a larger campaign as Hims & Hers continues to highlight its weight loss treatments. The ad ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.